Valantine Hannah 4
4 · CareDx, Inc. · Filed Jun 16, 2026
Research Summary
AI-generated summary of this filing
CareDx (CDNA) Director Valantine Hannah Sells Shares
What Happened
Valantine Hannah, a director of CareDx, was granted 9,795 restricted stock units (RSUs) on 2026-06-12 (reported as an award at $0 cost) and sold 12,103 CareDx shares in an open-market transaction on 2026-06-15 for a weighted average price of $23.11, totaling approximately $279,728. The RSU grant vests 100% on the earlier of the one-year anniversary of the grant or the day before the first annual meeting after the grant, subject to continued service.
Key Details
- Grant: 9,795 RSUs on 2026-06-12 (reported as acquisition A at $0) — vesting: 100% at earlier of 1-year anniversary or day before first annual meeting after grant (service condition).
- Sale: 12,103 shares on 2026-06-15 (sale, S) — weighted average price $23.11; total proceeds ≈ $279,728. Sales executed at prices ranging $23.00–$23.30.
- Sale executed pursuant to a Rule 10b5-1 trading plan adopted Dec 11, 2025.
- Shares owned after the transactions are not specified in the provided filing.
- Filing date: 2026-06-16. No indication the Form 4 was filed late.
Context
RSU grants are awards that vest later (not immediate cash), so the 9,795 RSUs do not represent immediately tradable shares until vesting conditions are met. The June 15 sale was made under a pre-established 10b5-1 plan, which typically schedules trades in advance and is common for insiders. The sale value (~$280k) is a factual disclosure and should not be taken alone as a signal of the director’s views about the company.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-12+9,795→ 48,789 total - Sale
Common Stock
[F2][F3]2026-06-15$23.11/sh−12,103$279,728→ 36,686 total
Footnotes (3)
- [F1]The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.
- [F2]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.